COVID-19 vaccines: Janssen/Johnson & Johnson


The Johnson & Johnson’s Janssen (J&J) SARS-CoV-2 viral vector vaccine is the third COVID-19 vaccine that received emergency use authorization (EUA) by the FDA.

J&J has also received an EUA for administration of a single COVID-19 vaccine booster dose for individuals 18 years of age and older, two months after completion of the J&J primary series, five months after completion of the Pfizer-BioNTech primary series or six months after completion of the Moderna primary series.

However, mRNA COVID-19 vaccines are preferred for the primary series and booster dose, over the J&J COVID-19 vaccine for the prevention of COVID-19 for those 18 years of age and older due to the risk of rare adverse events such as thrombosis with thrombocytopenia (TTS).

Currently authorized or approved mRNA COVID-19 vaccines are Pfizer-BioNTech’s and Moderna’s mRNA vaccines.

Find clinical vaccine guidance from the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC) and other health organizations.


Learn more about FDA information on COVID-19 vaccines and the FDA's Vaccines and Related Biological Products Advisory Committee.


Learn more about the CDC's Advisory Committee on Immunization Practices. The CDC offers a guide on preparing for COVID-19 vaccination for health care professionals and a COVID-19 vaccination communications tool kit for medical centers, clinics and clinicians.

Explore featured AMA news and media about the Janssen/J&J COVID-19 vaccine, including the AMA COVID-19 Video Update.

AMA COVID-19 Video Update

AMA webinar series: What physicians need to know about COVID-19 vaccines

News highlights

Media coverage